Chip-Man Technologies Ltd. of Tampere, Finland, and TCS Cellworks of Botolph Claydon, UK, have announced a collaboration in which the former’s Cell-IQ platform will be offered with the latter’s AngioKit model. The kit is a system of human cell lines used to quantitatively assess pro- and antiangiogenic agents in a 24-well-plate format. Cell-IQ is a continuous cell culturing platform that performs real-time analysis of morphological and physiological events in living cells by using machine vision technology. The combined kit and platform will increase throughput and content in angiogenesis research. In other news, Chip-Man Technologies has agreed to work with Arctic Diagnostics Oy of Turku, Finland, to develop fluorescence detection modules for use with the Cell-IQ. The development will enable simultaneous measurement and analysis of cells in the same culture using phase contrast and fluorescence detection. This will allow monitoring of drug reactions with minimal trauma to the cells.